Skip to main content

Drug utilization review educational bulletins

August 2023

 

No Added Benefit from Concomitant Use of GLP-1 Agonists and DPP-4 Inhibitors (PDF)

 

New Resources Available for Perinatal Mental Health Conditions (PDF)

 

June 2023

 

FDA Approves First Over-the-Counter Naloxone Nasal Spray (PDF)

 

Updated Guidance by the CDC and FDA for Prescribing Opioids (PDF)

 

May 2023

 

Clinical Review: Management of Acute Postpartum Pain (PDF)

 

January 2023

 

2022 Immunization Update: Mpox, HepB, Influenza, COVID-19, Pneumococcal, Zoster (PDF)

 

Improving the Quality of Care: Treatment of Latent Tuberculosis Infection (PDF)

 

Risks to Patients Exposed to Xylazine in Illicit Drugs (PDF)

 

Removal of DATA-Waiver (X-Waiver) Requirement (PDF)

 

May 2022

 

Submitting Quality Data to the California Immunization Registry (CAIR2) (PDF)

 

March 2022

 

Improving the Quality of Care: Legislative Impact on the Use of Naloxone (PDF)

 

February 2022

 

Professional Organizations Push for Recall of Buprenorphine Dental Warning (PDF)

 

September 2021

 

UPDATED: Drug Safety Communication: Voluntary Recall of Varenicline (Chantix) Due to Nitrosamine (PDF)


 
2021 Immunization Updates: COVID-19, Influenza, and Meningococcal Disease (PDF)

 

August 2021

 

Drug Safety Communication: FDA Requests Removal of Pregnancy Contraindication for Statins (PDF)

 

April 2021

 

Drug Safety Communication: Potential Increased Arrhythmia Risk from Lamotrigine (PDF)

 

March 2021

 

Clinical Review: Recommendations for the Tapering of Benzodiazepines (PDF)

 

January 2021

 

Clinical Review: Recommendations for the Management of Acute Dental Pain (PDF)

 

August 2020

 

Clinical Review: 2020 Standards of Care for Treatment of Type 2 Diabetes (PDF)

 

August 2019

 

CDC, ACIP release flu vaccine recommendations for upcoming flu season (PDF)

 

CDC, ACIP release human papillomavirus vaccination for adults: updated recommendations (PDF)

 

 

July 2019

 

CDC releases interim infection prevention and control recommendations for measles

 

California drug take-back program


Accelerating opioid safety: ambulatory care toolkit (PDF)

 

 

July 2018

 

Drug safety communication: adverse effects from fluoroquinolone antibiotics (PDF)

 

 

March 2018

 

In the pharmacy: pharmacists furnishing nicotine replacement products (PDF)

 

 

February 2018

 

Drug safety communication: new age limit for opioid cough and cold medicines (PDF)

 

 

September 2017

 

Alert: online report to the Vaccine Adverse Event Reporting System (VAERS) (PDF)


2017 immunization updates: influenza, HepA, meningococcal, HPV, adult vaccines (PDF)

Also of interest: